Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 9/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.47 |
| ▸ | MAPKAPK3 | Q16644 | 5/20 | 0.47 |
| ▸ | MAPK6 | Q16659 | 5/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.47 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 4/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5372930 | 0.91 | MKNK1 (0.49) | MAP2K4MAPK1MAPKAPK3MAPK6MKNK1 | |
| SCHEMBL5374429 | 0.87 | MAP2K4 (0.55) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL14514472 | 0.85 | MKNK1 (0.60) | MAP2K4MAPK1MAPKAPK3MAPK6MKNK1 | |
| SCHEMBL7531141 | 0.85 | JAK2 (0.56) | MAP2K4MAPK1MKNK1TTKMAPK8 | |
| SCHEMBL5377872 | 0.85 | NTRK1 (0.47) | MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL5398248 | 0.85 | AURKA (0.58) | MAP2K4MKNK1TTKMAPK8LRRK2 | |
| SCHEMBL8267916 | 0.84 | MKNK1 (0.41) | MAP2K4MAPK1MKNK1TTKMAPK8 | |
| SCHEMBL5382770 | 0.84 | FGFR1 (0.53) | MAP2K4MKNK1TTKMAPK8AXL | |
| SCHEMBL12127292 | 0.83 | IDO1 (0.50) | MAPK14 | |
| SCHEMBL29417890 | 0.83 | IDO1 (0.50) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | claimed |
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | claimed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | claimed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | MAP2K4 130/4885MAPK1 1/4885MAPKAPK3 13/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | MAP2K4 3021/4885MAPK1 2816/4885MAPKAPK3 1964/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MAP2K4 385/4885MAPK1 52/4885MAPKAPK3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.